drugset / Trial / NCT04262193
Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder
Phase 2
Terminated
37 enrolled
Wayne State University
Ascension Brighton Center for Recovery · collabHenry Ford Health System · collab
RandomizedParallel-groupQuadruple-blindBasic science
Summary
Summary of Study Protocol. This project is designed to test neurobehavioral mechanisms underlying effects of the dual orexin-1/2 receptor antagonist suvorexant on sleep efficiency and opioid abstinence, and whether these outcomes are independent of one another. This will be the first study to investigate whether suvorexant improves outpatient opioid abstinence and sleep efficiency; and whether improving sleep mediates the improved opioid abstinence outcome. 120 participants with opioid use disorder (OUD) will complete this intent-to-treat study.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2024-07-30
- Completion
- 2024-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suvorexant | Small molecule | 20 mg | Oral |